Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Recruiting · Phase 3 · NCT06510374
Conditions: Intermediate Risk Non-Muscle Invasive Bladder Cancer
At a glance
- Research payments reported, 2025
- $546,844
- U.S. investigators named
- 21
- Sites paid
- 22
- Planned or actual enrollment
- 454
About the trial
- Sponsor
- Ferring Pharmaceuticals
- Tested
- Nadofaragene Firadenovec (drug)
- Dates
- Started 2024-10-01; completion 2032-09-30
- Results posted
- Not yet
A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
From ClinicalTrials.gov, last updated 2026-10-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ferring Pharmaceuticals As reported $546,844 in research payments for this study in 2025 (51 payments).
Products named: Adstiladrin
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Christopher Keel, DO Urology · Fairhope, AL
- Madhumitha C. Reddy, D.O Urology · Murrieta, CA
- Amirali Salmasi, M.D Urology · San Diego, CA
- William M. Schiff, M.D. Urology · Fresno, CA
- Edward M. Uchio, MD Urology · Orange, CA
- Vikram M. Narayan, MD Urology · Atlanta, GA
- David C. Lieber, M.D. Urology · Springfield, IL
- Philippe Nabbout, MD Urology · Wichita, KS
- Patrick J. Hensley, M.D. Urology · Lexington, KY
- Gautum Agarwal, MD Urology · Saint Louis, MO
- Andrew F. Trainer, M.D. Urology · Omaha, NE
- Sandip M. Prasad, MD, MPHIL Urology · Morristown, NJ
- Mitchell D. Efros, MD Urology · Garden City, NY
- Izak Faiena, MD Urology · Bronx, NY
- Jed C. Kaminetsky, MD Urology · New York, NY
- Badar M. Mian, M.D. Urology · Albany, NY
- John M. Rutkowski, M.D. Urology · Sanborn, NY
- Alberto Martini, MD Urology · Cincinnati, OH
- Neal Shore, DR Urology · Myrtle Beach, SC
- Raj Satkunasivam, M.D., FRCSC Urology · Houston, TX
- Michael B. Williams, M.D. Urology · Virginia Beach, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Urology of Virginia PLLC $40,780
- University of Cincinnati $40,436
- Emory University Hospital, GA $38,454
- Folio Clinical Research Organization LLC $37,750
- The Regents of the University of California $35,216
- Houston Methodist Hospital, TX $34,699
- Adult and Pediatric Urology PC $33,760
- Mercy Research $33,575
- Morristown Medical Center, NJ $32,276
- Urology Associates of Central California Medical Group Inc $30,526
- The Research Foundation for The State University of New York $28,826
- Blessing Hospital, IL $24,000
- Integrated Medical Professionals PLLC $23,272
- University of Kentucky Research Foundation $22,200
- Wichita Urology Group PA $19,996
- Bronx Veterans Medical Research Foundation Inc $13,770
- South Alabama Medical Science Foundation $13,700
- Carolina Urologic Research Center LLC $12,800
- Accumed Research Associates $10,375
- Sabai LLC $7,750
- Clinical Biosafety Services LLC $6,500
- Albany Medical College $6,183
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.